Cardiology Update

AUGUST 4, 2024

Despite proven benefits in reducing morbidity and mortality, many heart failure (HF) patients do not receive optimal guideline-directed medical therapy (GDMT). The 2021 European Society of Cardiology guidelines recommend guideline-directed medical therapy (GDMT) for patients with HF with reduced ejection fraction (HFrEF).

Heart Failure 119

Heart Failure ACE Inhibitor COVID-19 Quality of Life 119

Open Heart

APRIL 24, 2024

Introduction Heart failure (HF) incidence is increasing in older adults with high hospitalisation and mortality rates. Results Data were collected in April 2012 to January 2014 and in June 2021 to December 2022. Treatment is complicated by side effects and comorbidities. Statistical significance is determined at p<0.05.

Heart Failure 52

Heart Failure Preserved Ejection Fraction ACE Inhibitor Pharmacology 52

Open Heart

FEBRUARY 17, 2024

Objective To evaluate stress, depression and quality of life among community-dwelling patients with heart failure (HF) and evaluate their effect on perceived medication adherence in a socioeconomically challenged setting. were on ACE inhibitors/angiotensin receptor blockers and 54.9% The mean age was 61.3±17.36

Heart Failure 40

Heart Failure Quality of Life ACE Inhibitor COVID-19 40

Open Heart

NOVEMBER 8, 2023

Background Currently, there is no head-to-head comparison of novel pharmacological treatments for heart failure with reduced ejection fraction (HFrEF). Methods Randomised controlled trials (RCTs) were identified from Medline, Scopus up to June 2021.

Heart Failure 52

Heart Failure ACE Inhibitor Outcomes Pharmacology 52

EMS 12-Lead

MAY 8, 2022

1] In their publication, Sclarovsky and Birnbaum discovered that with each grading escalation there is less salvageable myocardium and higher likelihood of heart failure at hospital discharge (an inversely proportional relationship). ACE inhibitors, or potassium-sparing diuretics), are particularly susceptible.

ACE Inhibitor 52

ACE Inhibitor Ischemia Physiology STEMI 52

Open Heart

DECEMBER 2, 2024

Introduction Heart failure with reduced ejection fraction (HFrEF) guidelines recommend ‘four pillars’ of medical therapy and device therapy if left ventricular ejection fraction (LVEF) remains ≤35% after 3 months optimum medical therapy. Results Between June 2021 and August 2022, 49 patients were recruited.

ACE Inhibitor 52

ACE Inhibitor Heart Failure Cardiomyopathy Outcomes 52